Spots Global Cancer Trial Database for Ulipristal Acetate in Symptomatic Uterine Fibroid

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Ulipristal Acetate in Symptomatic Uterine Fibroid

Official Title: The Effectiveness and Safety of Ulipristal Acetate in Women With Symptomatic Uterine Fibroid

Study ID: NCT04132349

Conditions

Uterine Fibroid

Heavy Menstrual Bleeding

Interventions

Ulipristal Acetate 5 mg

Study Description

Brief Summary: This study evaluates the effectiveness and safety of ulipristal acetae (UPA) in women with symptomatic uterine fibroids. Those who fulfilled inclusion/exclusion criteria will be treated UPA at daily dose of 5mg.

Detailed Description: There is increasing evidence approving role of medical therapy in treatment of symptomatic uterine fibroid, in the context of women's desire to preserve fertility or not to undergo operation. Among these hormonal therapies, ulipristal acetate (UPA) is an orally administered selective progesterone receptor modulator commonly prescribed for treatment of uterine fibroid. This agent acts on causing apoptosis of the muscle cells inside the tumor and reducing the tumor matrix in case of uterine fibroid. UPA at daily dose of 5 mg has been shown to decrease menstrual blood loss and reduce tumor size after 13 consecutive weeks of treatment.